Professor Nancy Ip is a globally acclaimed neuroscientist celebrated for her groundbreaking work in molecular neuroscience. Her research centers on uncovering the underlying mechanisms of neurodegenerative diseases, particularly Alzheimer’s disease, with the goal of developing innovative therapeutic strategies and new drugs.

By combining multi-omics approaches with human and functional studies, she has made significant contributions to the identification of diagnostic biomarkers and promising therapeutic targets for Alzheimer’s disease.

Professor Ip serves as President of The Hong Kong University of Science and Technology (HKUST), where she also holds the title of The Morningside Professor of Life Science and Director of the State Key Laboratory of Nervous System Disorders. In addition, she is the Center Director of the Hong Kong Center for Neurodegenerative Diseases (HKCeND). She is widely respected for her dedication to translating scientific discoveries into meaningful innovations and for mentoring the next generation of researchers.

With an outstanding publication record of more than 320 scientific papers and over 44,000 citations (Google Scholar), Professor Ip also holds 70 patents. She has been elected to several of the world’s most prestigious academies, including the Chinese Academy of Sciences, the US National Academy of Sciences, the American Academy of Arts and Sciences, the World Academy of Sciences, and the Hong Kong Academy of Sciences. She currently serves as a member of the Leadership Group of the Davos Alzheimer’s Collaborative.

Throughout her career, Professor Ip has received numerous high-profile awards and honors, such as the National Natural Science Awards, the L’ORÉAL-UNESCO For Women in Science Award, and recognition as one of the 10 Science Stars of China by Nature.

Dr. Lindsay is currently the Chairman and CEO of Zebra Biologics Inc. He has over 30 years of experience in the biopharmaceutical industry, which started in 1988 when he joined Regeneron Pharmaceuticals Inc. in New York as co-founding scientist. As VP of Neurobiology, he led Regeneron’s neuroscience and preclinical groups for a decade. In 1998, Dr. Lindsay joined Millennium Pharmaceuticals, where he served as the CSO of the subsidiary Millennium Biotherapeutics Inc. in Cambridge, MA, and as Senior VP of the parent company. He subsequently joined diaDexus Inc., a molecular diagnostic and cancer target discovery company in San Francisco, as their CSO until 2004. At that time, he opened a consulting business called Milestone Consulting. Since then, Dr. Lindsay has served on the boards and scientific advisory boards of several private and public companies, including Neuro3D, Rinat Inc., Serono S.A., Arqule Inc., Neurocentrx Ltd., Sequenom Inc., and Depixus S.A.S. 

Dr. Lindsay has authored over 150 peer-reviewed scientific publications and book chapters, primarily in the field of neurotrophic growth factors and nervous system development and disorders. 

Prof. Fanny Ip is currently the Chief Scientific Officer of Hong Kong Center for Neurodegenerative Diseases, amid affiliates at the State Key Laboratory of Molecular Neuroscience in the Division of Life Science of The Hong Kong University of Science and Technology (HKUST). Prof. Ip has extensive experiences in project management for both academic and commercial collaboration. She has successfully overseen a number of government-funded research projects to completion. She has published 69 scientific papers in peer-reviewed journals, and a co-inventor of 35 granted patents. She has successfully licensed out patented technologies on AD therapeutics for further preclinical development in US. 

Dr. May Liang participated in the establishment of the Shanghai Biomedicine Fund in 2020 and serves as a fund partner. In 2025, she also took on the role of President of the Hong Kong Biotechnology Fund. She has over twenty years of experience in cross-border investment banking, having previously served as the Deputy Executive Vice President, head of Corporate Finance and Capital Markets of China Merchants Securities International, as well as Managing Director of Global Banking and General Manager of Financing and Advisory in HSBC in China, and Deputy General Manager of China Southern Securities Investment Banking Department. 

She has led projects with financing amounts exceeding $30 billion, including industry-leading companies such as Innovent Biologics, WuXi Biologics, Venus MedTech, Ascletis Pharma Inc., SANY Heavy Industry, SAIC Motor, and Fuyao Glass. She has also led investments in top companies in sectors such as silicon-based biomimetics, surgical robotics, LEPU ScienTech Medical Technology, Tofflon and Brattea.

Ms. Priscilla Chan has tremendous scientific and regulatory affairs executive experience in global filing of pharmaceutical and veterinary drugs. She has over fifteen years of experience playing different key roles in biopharmaceutical industry, including Regulatory Affairs, Manufacturing Operations and Business Development. She was in-charge of global regulatory strategic planning and execution in drug development. She has strong operational and team management skills in pharmaceutical industry. 

Mr. Otto To is a member of the Hong Kong Institute of Certified Public Accountants and has extensive experience in finance, strategic planning, operations, and business development.

Mr. To previously served as Business Director (China Business) of Hong Kong Center for Neurodegenerative Diseases, where he focused on commercializing research and cultivating strategic partnerships. Prior to that, he was Chief Executive Officer and Executive Director of Vincent Medical Holdings Limited (HKEX: 1612), a publicly listed company in the healthcare sector.

Throughout his career, Mr. To has held key leadership roles encompassing the successful execution of an initial public offering, the translation of research projects into commercial ventures, and the evaluation and negotiation of certain M&A transactions.